Bafna Pharmaceuticals Ltd (BAFNAPH) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 852453,
    "name": "Bafna Pharma.",
    "stock_name": "Bafna Pharma.",
    "full_name": "Bafna Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/bafna-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "156.50",
    "chg": -1.1,
    "chgp": "-0.7%",
    "dir": -1,
    "prev_price": "157.60",
    "mcapval": "356.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 532989,
    "symbol": "BAFNAPH",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE878I01022",
    "curr_date": "Jun 18",
    "curr_time": "",
    "bse_nse_vol": "30.35 k",
    "exc_status": "Active",
    "traded_date": "Jun 18, 2026",
    "traded_date_str": "2026 06 18",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://marketsmojo.motilaloswal.com/MOSL-Landingstocks-analysis/bafna-pharma-852453-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Bafna Pharmaceuticals Ltd Valuation Shifts Signal Price Attractiveness Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-ltd-valuation-shifts-signal-price-attractiveness-challenges-3986280",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/BafnaPharmaceut_valuationdot_3986280.png",
        "date": "2026-05-12 08:00:58",
        "description": "Bafna Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters shift notably, moving from fair to expensive territory. This change, coupled with a recent upgrade in its Mojo Grade from Strong Sell to Sell, highlights evolving market perceptions and raises questions about the stock’s price attractiveness relative to its historical and peer benchmarks."
      },
      {
        "title": "Bafna Pharmaceuticals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/bafna-pharmaceuticals-ltd-is-rated-sell-3985314",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/BafnaPharmaceut_mojoScore_3985314.png",
        "date": "2026-05-11 10:11:13",
        "description": "Bafna Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Bafna Pharmaceuticals Ltd Valuation Shifts to Fair Amid Mixed Market Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-ltd-valuation-shifts-to-fair-amid-mixed-market-performance-3976717",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/BafnaPharmaceut_valuationdot_3976717.png",
        "date": "2026-05-06 08:00:36",
        "description": "Bafna Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade as of late April 2026. Despite a recent day decline of 3.76%, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a more balanced price attractiveness compared to its historical and peer averages within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Bafna Pharmaceuticals Ltd Upgraded to Sell on Technical Improvements Despite Expensive Valuation",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/bafna-pharmaceuticals-ltd-upgraded-to-sell-on-technical-improvements-despite-expensive-valuation-3969600",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/BafnaPharmaceut_mojoScore_3969600.png",
        "date": "2026-04-30 08:16:04",
        "description": "Bafna Pharmaceuticals Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 29 Apr 2026, reflecting a nuanced shift in its technical outlook despite persistent valuation and fundamental challenges. The upgrade is primarily driven by improved technical indicators, while valuation metrics have become more expensive and financial trends remain flat, prompting a cautious stance for investors."
      },
      {
        "title": "Bafna Pharmaceuticals Downgraded to Strong Sell Amid Valuation and Technical Concerns",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/bafna-pharmaceuticals-downgraded-to-strong-sell-amid-valuation-and-technical-concerns-3963779",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/BafnaPharmaceut_mojoScore_3963779.png",
        "date": "2026-04-27 08:13:46",
        "description": "Bafna Pharmaceuticals Ltd has been downgraded from a Sell to a Strong Sell rating as of 24 April 2026, reflecting deteriorating technical indicators and an expensive valuation profile despite its strong long-term returns. The micro-cap pharmaceutical company faces challenges across quality, valuation, financial trends, and technical parameters, prompting a reassessment of its investment appeal."
      },
      {
        "title": "Bafna Pharmaceuticals Gains 2.43%: 2 Key Factors Driving the Week",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-gains-243-2-key-factors-driving-the-week-3962552",
        "imagepath": "",
        "date": "2026-04-25 15:01:02",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>Apr 20:</strong> Stock opens strong at Rs.142.10 (+4.72%)</p>\n                    <p><strong>Apr 21:</strong> Sharp correction to Rs.135.00 (-5.00%)</p>\n                    <p><strong>Apr 23:</strong> Surges to upper circuit at Rs.138.73 amid strong buying</p>\n                    <p><strong>Apr 24:</strong> Valuation shifts signal price attractiveness challenges</p>\n                    <p><strong>Apr 24:</strong> Week closes at Rs.139.00 (+2.43% weekly gain)</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.135.70</div></div>\n                    <div class..."
      },
      {
        "title": "Bafna Pharmaceuticals Ltd Valuation Shifts Signal Price Attractiveness Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-ltd-valuation-shifts-signal-price-attractiveness-challenges-3960027",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/BafnaPharmaceut_valuationdot_3960027.png",
        "date": "2026-04-24 08:00:33",
        "description": "Bafna Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an expensive rating, prompting a reassessment of its price attractiveness amid evolving market dynamics and peer comparisons within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Bafna Pharmaceuticals Ltd Locks at Upper Circuit With 5.87% Gain — Buyers Queue, Sellers Absent",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-ltd-surges-to-upper-circuit-amid-strong-buying-pressure-3959504",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/BafnaPharmaceut_stocks_hitting_upper_circuit_3959504.png",
        "date": "2026-04-23 15:00:08",
        "description": "At Rs 138.73, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Bafna Pharmaceuticals Ltd locked at its upper circuit of 5.87% on 23 Apr 2026, with buyers queuing and no sellers willing to part with shares."
      },
      {
        "title": "Bafna Pharmaceuticals Declines 6.41% Amid Mixed Signals and Valuation Shift",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-declines-641-amid-mixed-signals-and-valuation-shift-3952408",
        "imagepath": "",
        "date": "2026-04-18 15:00:05",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>13 Apr:</strong> Stock hits lower circuit amid heavy selling pressure</p>\n                    <p><strong>16 Apr:</strong> Technical and valuation improvements prompt rating upgrade</p>\n                    <p><strong>17 Apr:</strong> Stock surges to upper circuit on strong buying interest</p>\n                    <p><strong>17 Apr:</strong> Valuation shifts signal improved price attractiveness</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.145.00</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"sta..."
      }
    ],
    "total": 15,
    "sid": "852453",
    "stock_news_url": "https://marketsmojo.motilaloswal.com/news/bafna-pharmaceuticals-852453"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "01-Jun-2026",
      "details": "Newspaper Publication for the Audited Financial Results of the Company for the Quarter & Year ended March 31 2026 as published in Financial Express and Makkal Kural on May 31 2026.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of The Board Meeting Held On May 29 2026",
      "datetime": "29-May-2026",
      "details": "We hereby inform you that the Board of Directors in their meeting held on May 29 2026 inter-alia considered and approved the Audited Financial Results of the Company along with the Auditors Report issued by the Statutory Auditors of the Company for the Quarter and Year ended March 31 2026.",
      "source": "BSE"
    },
    {
      "caption": "Audited Financial Results For Quarter And Year Ended March 31 2026",
      "datetime": "29-May-2026",
      "details": "We herewith enclose the Audited Financial Results of the Company along with the Statutory Auditors Report for the Quarter and Year ended March 31 2026 as approved by the Board of Directors of the Company at its meeting held on May 29 2026.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Bafna Pharmaceuticals Ltd has declared <strong>6%</strong> dividend, ex-date: 19 Sep 13",
          "dt": "2013-09-19",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Bafna Pharmaceuticals Ltd Valuation Shifts Signal Price Attractiveness Challenges

2026-05-12 08:00:58

Bafna Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters shift notably, moving from fair to expensive territory. This change, coupled with a recent upgrade in its Mojo Grade from Strong Sell to Sell, highlights evolving market perceptions and raises questions about the stock’s price attractiveness relative to its historical and peer benchmarks.

Bafna Pharmaceuticals Ltd is Rated Sell

2026-05-11 10:11:13

Bafna Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Bafna Pharmaceuticals Ltd Valuation Shifts to Fair Amid Mixed Market Performance

2026-05-06 08:00:36

Bafna Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade as of late April 2026. Despite a recent day decline of 3.76%, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a more balanced price attractiveness compared to its historical and peer averages within the Pharmaceuticals & Biotechnology sector.

Bafna Pharmaceuticals Ltd Upgraded to Sell on Technical Improvements Despite Expensive Valuation

2026-04-30 08:16:04

Bafna Pharmaceuticals Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 29 Apr 2026, reflecting a nuanced shift in its technical outlook despite persistent valuation and fundamental challenges. The upgrade is primarily driven by improved technical indicators, while valuation metrics have become more expensive and financial trends remain flat, prompting a cautious stance for investors.

Bafna Pharmaceuticals Downgraded to Strong Sell Amid Valuation and Technical Concerns

2026-04-27 08:13:46

Bafna Pharmaceuticals Ltd has been downgraded from a Sell to a Strong Sell rating as of 24 April 2026, reflecting deteriorating technical indicators and an expensive valuation profile despite its strong long-term returns. The micro-cap pharmaceutical company faces challenges across quality, valuation, financial trends, and technical parameters, prompting a reassessment of its investment appeal.

Bafna Pharmaceuticals Gains 2.43%: 2 Key Factors Driving the Week

2026-04-25 15:01:02

Key Events This Week Apr 20: Stock opens strong at Rs.142.10 (+4.72%) Apr 21: Sharp correction to Rs.135.00 (-5.00%) Apr 23: Surges to upper circuit at Rs.138.73 amid strong buying Apr 24: Valuation shifts signal price attractiveness challenges Apr 24: Week closes at Rs.139.00 (+2.43% weekly gain) Week OpenRs.135.70 <div class...

Bafna Pharmaceuticals Ltd Valuation Shifts Signal Price Attractiveness Challenges

2026-04-24 08:00:33

Bafna Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an expensive rating, prompting a reassessment of its price attractiveness amid evolving market dynamics and peer comparisons within the Pharmaceuticals & Biotechnology sector.

Bafna Pharmaceuticals Ltd Locks at Upper Circuit With 5.87% Gain — Buyers Queue, Sellers Absent

2026-04-23 15:00:08

At Rs 138.73, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Bafna Pharmaceuticals Ltd locked at its upper circuit of 5.87% on 23 Apr 2026, with buyers queuing and no sellers willing to part with shares.

Bafna Pharmaceuticals Declines 6.41% Amid Mixed Signals and Valuation Shift

2026-04-18 15:00:05

Key Events This Week 13 Apr: Stock hits lower circuit amid heavy selling pressure 16 Apr: Technical and valuation improvements prompt rating upgrade 17 Apr: Stock surges to upper circuit on strong buying interest 17 Apr: Valuation shifts signal improved price attractiveness Week OpenRs.145.00 Week Close<div class="sta...

View All News